Clinical Trials
2 trialsNCT02188537 2019-06-26
Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma
Swiss Cancer Institute
Phase 2 Completed
NCT01164709 2019-05-15
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Swiss Cancer Institute
Phase 1 Completed